BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
BIKAM and Dalton medicinal chemistry, have jointly announced an exclusive worldwide collaboration and agreement to discover and develop new therapeutics for unmet needs in ophthalmology.
Dalton Medicinal Chemistry will utilize their proprietary insights to advance several novel classes of compounds against selected BIKAM targets. BIKAM will advance these agents with their cutting edge battery of biological assays and delivery methodologies.
David Garvey, VP, Chemistry at BIKAM commented: "We are pleased to have the opportunity to work with the creative team at Dalton Medicinal Chemistry in the discovery and development of new entities for treating eye diseases. Their expertise, together with our propriety and leading position will quickly deliver important new medicines."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.